AXAxinet
Menu
Finance

Live market screen

Commercial Space Company Risk / Opportunity Ranking

Opportunity/risk view across launch, satellites, SAR, earth observation, defense demand, financing events, and execution risk.

Updated June 27, 2026

Companies analyzed
438
Ranked rows
876
Evidence links
356
Rows per page
20

Opportunity view

Showing rows 161-180 of 438; 20 rows per page.

Sorted by raw opportunity score
RankCompanyScoreThesis / Evidence
161
Antaris Inc.
lowweak
Opp 2
Risk 2

Thesis: Antaris may have strategic opportunity based on the membership rationale referencing private space software work, LEO ISR/optical communications architecture, a JANUS-2 mission, and self-healing satellite capability for the U.S. Space Force, but the reviewed sources includes no retained recent evidence window-window evidence to support scoring that thesis now.

Why now: There is no retained 90-day evidence in these reviewed sources despite references to evidence in earlier processing. Recency-sensitive conclusions therefore cannot be made from the local reviewed sources.

Caveats: Membership rationale references older evidence but no article IDs are provided with accessible summaries in these reviewed sources body. No representative articles or retained evidence are included. Low score reflects evidence absence, not a negative business judgment.

162
Antaris Inc.
lowweak
Opp 2
Risk 1

Thesis: There is a faint opportunity signal because the phase2 rationale states Antaris appeared as part of an investment issuer's portfolio after a $28 million Series A, which suggests access to capital, but the reviewed sources does not provide the underlying citable event text in the scoring evidence fields.

Why now: Why now is weak: the only reviewed sources signal is the phase2 rationale mentioning a post-Series A portfolio reference tied to article, but no representative article summary or direct evidence row is included here to establish timing or business impact.

Caveats: The cited Series A context appears only in phase2 rationale rather than in stronger scoring evidence fields. No product, customer, or execution evidence is provided.

163
Applied Atomics
lowweak
Opp 2
Risk 3

Thesis: Applied Atomics may have long-horizon optionality as a startup developing in-space mobility/orbital logistics concepts, but the reviewed sources provide no available article or evidence inside the recent evidence window to support a stronger opportunity score.

Why now: There is no available dated evidence in the reviewed sources after recent evidence filtering, so recency-based ranking support is weak.

Caveats: No representative articles or evidence are available after recent evidence filtering for ranking support. The phase2 membership rationale mentions a $4M pre-seed and Star Reacher Network, but the cited supporting articles are not provided with usable article summaries or evidence in these reviewed sources.

164
Astranis Space Technologies
lowweak
Opp 2
Risk 2

Thesis: Phase-2 rationale states Astranis was selected by the U.S. Space Force for the Andromeda contract for next-generation space domain awareness/surveillance satellites, which would be positive if current and retained, but the present reviewed sources contain no in-window evidence to substantiate it.

Why now: The current batch retains no representative articles or evidence within the 90-day recent evidence window for Astranis, so the reviewed sources does not provide a current dated catalyst despite the phase-2 rationale.

Caveats: No retained evidence after recent evidence window. Phase-2 rationale mentions duplicate article versions; duplicates would not be independent confirmation anyway.

165
Astrobotic Technology
lowweak
Opp 2
Risk 2

Thesis: The membership rationale says Astrobotic operates the Griffin lunar lander and is a CLPS contractor, which is strategically relevant for a 1 year+ horizon, but the reviewed sources supplies no available within the recent evidence window direct positive evidence or dated article summaries for scoring.

Why now: The rationale references articles, and: but no corresponding available evidence remains available for direct scoring after recent evidence filtering.

Caveats: Lunar lander category fit does not equal thesis attractiveness. Coverage debug shows zero available evidence after recent evidence window. Without direct execution, funding, contract-conversion, or mission-status evidence, scores should remain conservative.

166
Astrolight
lowweak
Opp 2
Risk 1

Thesis: Membership rationale indicates Astrolight is a private space/defense startup developing laser communication terminals for space, with ESA contracts and deployed terminals, which could support a 1 year+ growth thesis in optical communications if verified by direct evidence.

Why now: Why now is weak because the reviewed sources cites support article: in membership rationale, but no, article summary, or retained evidence are provided after the 90-day filter.

Caveats: Potentially strong fundamentals are only referenced in membership rationale without citable article details. Coverage data shows zero articles after recent evidence window and zero evidence after recent evidence window. Private-company status also limits external validation in these reviewed sources.

167
Astrolight UAB
lowweak
Opp 2
Risk 2

Thesis: Astrolight UAB may have a long-horizon opportunity if it is providing optical hardware into a Kepler Communications ESA HydRON optical communications network effort, but the reviewed sources lack available direct evidence to confirm Astrolight's own contract position, scope, or recency.

Why now: There is no usable 'why now' beyond possible strategic relevance to optical communications. The reviewed sources provide no after-recent evidence window evidence to confirm current status.

Caveats: Phase-2 rationale references, but the reviewed sources does not include its or article summary. Relations marked context-only cannot be used as counterparty propagation evidence. Coverage debug shows zero evidence after recent evidence window.

168
Astrome
lowweak
Opp 2
Risk 1

Thesis: Reviewed evidence rationale says Astrome was among spacetech startups receiving India's RDI fund support, which is directionally positive as non-dilutive or supportive capital context, but no underlying article or dated event evidence is present in the available recent evidence window dataset.

Why now: Why now is weak because the support exists only in the phase-2 rationale; coverage data shows zero evidence after recent evidence window, so timing and durability of the funding support cannot be verified from local evidence.

Caveats: No direct article or event evidence is available after recent evidence window. Government-support statement is not accompanied by a dated in-window source in the reviewed sources. Low confidence due to sparse evidence.

169
Atomos Space
lowweak
Opp 2
Risk 1

Thesis: A very modest opportunity case exists only because retained undated supporting context lists Atomos Space as an operating in-orbit servicing company, which at least suggests ongoing activity in a strategically relevant segment, but this is supporting article context rather than direct company event evidence.

Why now: Why now is limited and recency is uncertain: the only retained evidence is undated supporting context, so it cannot establish a fresh catalyst, only background relevance, article date_basis: undated).

Evidence
  • Space Index lists 'Atomos Space|Broomfield, Colorado, USA|operating' within 'In-Orbit Servicing & Assembly Companies.' This is undated supporting article context, not direct event proof. spaceindex.io

Caveats: The evidence is undated, and the reviewed sources explicitly says to treat undated external evidence as relevance context rather than recency proof. The retained rows are weak context and neutral polarity, not positive evidence. Same article repeated rows are not independent confirmation.

170
Azista Space
lowweak
Opp 2
Risk 2

Thesis: Reviewed evidence membership rationale says Azista Space built the satellite bus/payload for GalaxEye's Drishti Earth Observation Satellite, which implies real manufacturing participation and possible long-horizon opportunity, but no direct evidence or article are available in the served reviewed sources.

Why now: Why now is weak because there is no surviving 90-day evidence row in the reviewed sources to establish recency or momentum.

Caveats: Only membership rationale is available; no citeable direct evidence with are provided. Single-article universe increases fragility of inference.

171
Blackstar Orbital
lowweak
Opp 2
Risk 2

Thesis: The reviewed sources rationale suggests Blackstar Orbital is described as a hypersonic/reusable spacecraft testing partner with mention of a reusable hypersonic satellite concept, which could imply technology optionality if substantiated and, no provided in reviewed sources). However, the evidence retained here is not direct and no positive events are available after recent evidence window.

Why now: No near-term or durable catalyst can be established from retained evidence because coverage debug shows zero article IDs and zero evidence after recent evidence window.

Caveats: No are provided for the cited support articles in the reviewed sources. The reviewed sources explicitly characterizes the evidence as mostly partnership context rather than direct operating detail. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0.

172
Brightside Group S.A.
lowweak
Opp 2
Risk 2

Thesis: Membership rationale indicates Brightside is advancing a €415M sovereign satellite program and provides a sovereign satellite platform via partnership with SES, which could be meaningful if current, but the reviewed sources exposes no direct within the recent evidence window evidence or article summaries to substantiate a current opportunity thesis.

Why now: Why now is weak because no representative article or direct evidence survives in the ranking fields after recent evidence window; only membership rationale references without surfaced article content.

Caveats: No direct within the recent evidence window evidence is available in ranking fields. Membership rationale alone is weaker than surfaced company-specific event evidence. No negative thesis is supportable from the reviewed sources.

173
BULL Co., Ltd.
lowweak
Opp 2
Risk 1

Thesis: The membership rationale says BULL signed an agreement with Fujitsu to develop a high-precision space situational awareness service for Japan, which is directionally positive, but there is no retained within the recent evidence window article evidence or in the reviewed sources to support a stronger opportunity thesis.

Why now: No within the recent evidence window evidence were retained, so there is no strong timing signal for a 1 year+ ranking beyond weak membership context.

Caveats: Membership rationale references articles and, but the reviewed sources does not provide or retained evidence. Potential commercial significance cannot be sized from the reviewed sources.

174
Calian Group Ltd.
lowweak
Opp 2
Risk 1

Thesis: There is some older membership support that the Canadian Space Agency awarded Calian funds for RADARSAT+ ground-segment concept studies via article: which could indicate space-contract relevance, but no retained in-window evidence with supports a stronger current opportunity thesis.

Why now: Why now is weak because the reviewed sources retained no evidence after recent evidence window for Calian, so no current catalyst is evidenced.

Caveats: Reviewed evidence mentions: but provides no, preventing direct citation as scored evidence. No retained 90-day evidence. Opportunity case depends on uncited older context rather than current business-state confirmation.

175
CAS Space
lowweak
Opp 2
Risk 3

Thesis: CAS Space may have long-horizon opportunity as a reusable rocket developer and launch provider, but the ranking reviewed sources provide no available supporting evidence within the recent evidence window.

Why now: There is no usable dated evidence available after recent evidence filtering, so the reviewed sources does not provide a clear timing catalyst.

Caveats: The membership rationale references an IPO and Lijian-1 launch activity, but those source articles are not included with ranking-usable details in these reviewed sources.

176
CAS Space
lowweak
Opp 2
Risk 2

Thesis: The reviewed sources rationale says CAS Space is among Chinese rocket/satellite companies advancing IPO or pre-IPO plans, which could be a strategic opportunity signal if supported by company-specific evidence (: and: no provided in reviewed sources).

Why now: There is no verified current catalyst in retained evidence. IPO/pre-IPO framing could matter on a 1 year+ horizon, but recency and milestone state cannot be confirmed here because no dated evidence are available after recent evidence window.

Caveats: No are provided for the cited support articles in the reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. IPO/pre-IPO mention is only in reviewed sources rationale, not in retained direct evidence.

177
Citra Space Corp
lowweak
Opp 2
Risk 1

Thesis: The membership rationale says Citra Space raised a $15M Series A to advance space object identification technology, which would ordinarily be positive, but the reviewed sources provide no retained within the recent evidence window article evidence or to ground a stronger opportunity call.

Why now: There is no usable within the recent evidence window article evidence available for ranking; coverage data shows zero article IDs after recent evidence window and zero evidence after recent evidence window, so any current catalyst judgment would be speculative.

Caveats: Membership rationale references article, but the reviewed sources does not provide the article or retained ranking evidence inside the recent evidence window. Because direct evidence arrays are empty, the small positive score reflects only weak contextual possibility, not high-confidence attractiveness.

178
Cosmoserve Space
lowweak
Opp 2
Risk 2

Thesis: Reviewed evidence membership rationale says Cosmoserve Space is a private space sustainability company working on debris removal, with Pixxel providing a satellite bus for its demo mission. That suggests a real mission path, but there are no citeable direct evidence or in the served reviewed sources.

Why now: Why now is weak because the reviewed sources does not establish current demo timing or funding status with direct evidence after recent evidence window.

Caveats: Private company with thin visible evidence in these reviewed sources. Mission/demo status cannot be validated from available evidence.

179
Curtiss-Wright Corporation
lowweak
Opp 2
Risk 1

Thesis: Curtiss-Wright has modest contextual opportunity because the membership rationale describes it as a ruggedized electronics supplier benefiting from broader space spending, which could align with a durable 1 year+ strategic cycle if backed by company-specific orders or segment growth evidence (: unavailable in reviewed sources). But the reviewed sources contain no direct positive evidence within the recent evidence window.

Why now: Potentially relevant if broader space spending is increasing, but the reviewed sources provide no retained dated evidence, no current data, so timing and magnitude cannot be validated.

Caveats: No current evidence is provided for Relation/context evidence must not be used as counterparty propagation; reviewed sources notes context only. No available direct evidence after recent evidence window despite high article count considered.

180
Deloitte
lowweak
Opp 2
Risk 1

Thesis: There is some indication of meaningful space activity, but not enough retained direct evidence to make a strong 1 year+ opportunity call.

Why now: The reviewed sources rationale says Deloitte launched satellites for Project Constellation to test on-orbit cyber protections and contracted Spire to design, build, and operate satellites, citing article, but no or retained evidence row is available after recent evidence window, limiting confidence.

Caveats: The described activity comes only from membership rationale rather than retained evidence. Without retained dated evidence or, chronology and durability cannot be tested.

Risk view

Showing rows 61-80 of 438; 20 rows per page.

Sorted by raw risk score
RankCompanyScoreThesis / Evidence
61
Xoople
mediummedium
Opp 6
Risk 4

Thesis: Article-level context also highlights structural Earth observation monetization difficulty and long procurement cycles, creating real commercialization risk even after the raise.

Why now: Xoople closed a $130 million Series B on April 6, 2026/07 and articles say the capital is for building out its constellation; for a 1 year+ horizon, that financing can enable product and deployment progress, but the same dated coverage warns the market has historically been hard to monetize.

Evidence
  • Published April 7, 2026: article says Earth observation data is easy to promote but difficult to turn into profit, with long procurement processes and commercial market under-realization. techfundingnews.com
  • Published April 6, 2026: Xoople closed a $130 million Series B and is developing a satellite constellation to collect data aimed at deep learning models. techcrunch.com
  • Published April 6, 2026: Xoople closed a $130 million Series B for AI Earth mapping. techbuzz.ai

Caveats: Positive support is mostly supporting article context rather than positive evidence. Commercialization warning is article context, not a company-specific deterioration event. No direct customer, backlog, or launch milestone evidence is available.

62
AAC Clyde Space AB
lowweak
Opp 3
Risk 3

Thesis: There is no direct adverse evidence in the reviewed sources, so risk is moderate-low and mostly reflects inability to verify current contract progression, funding conversion, or execution status from available evidence (: unavailable in reviewed sources).

Why now: Why now is weak because the reviewed sources' recent evidence review and coverage data show zero available evidence after recent evidence window despite the membership rationale referencing a material contract.

Caveats: No current evidence is provided for Contract claim appears only in membership rationale, not in available direct evidence fields. No recency-confirmed follow-through evidence is available.

63
Aavuus
mediummedium
Opp 5
Risk 3

Thesis: Aavuus remains early-stage, and the evidence is supporting article context rather than direct positive events; the same article describes only pre-seed funding, which implies execution and scaling risk over a 1 year+ horizon.

Why now: The opportunity is timely because the retained article is dated June 9, 2026 and describes a current financing and product build phase rather than stale background context. That said, recency comes from source date/article date, and evidence grounding is still article-level rather than direct fact/events., June 9, 2026

Evidence
  • Aavuus has raised pre-seed funding from Maki.vc and is developing a global laser-based tracking network to improve collision avoidance and close a critical visibility gap in Low Earth Orbit. tech.eu

Caveats: Evidence is weak context and supporting article context, not direct structured positive event evidence. No explicit customer, contract, revenue, or regulatory milestone is cited. Same article appears in multiple rows and is not independent confirmation.

64
Applied Atomics
lowweak
Opp 2
Risk 3

Thesis: Risk is modestly elevated because the reviewed sources' membership rationale describes it as a startup that emerged from stealth and raised only a $4M pre-seed, implying early-stage execution and financing risk, but this is not backed by available dated evidence in the ranking payload.

Why now: There is no available dated evidence in the reviewed sources after recent evidence filtering, so recency-based ranking support is weak.

Caveats: No representative articles or evidence are available after recent evidence filtering for ranking support. The phase2 membership rationale mentions a $4M pre-seed and Star Reacher Network, but the cited supporting articles are not provided with usable article summaries or evidence in these reviewed sources.

65
Astrolab
lowweak
Opp 3
Risk 3

Thesis: No direct negative evidence is available; the main risk in this ranking is evidence insufficiency rather than a documented adverse development.

Why now: Why-now support is weak because coverage data shows no evidence after recent evidence window, so the cited lunar contract context cannot be refreshed from available evidence.

Caveats: Phase2 rationale cites, and: but no representative article or evidence are available for direct citation. Coverage data reports articles after recent evidence window = 0 and evidence after recent evidence window = 0. Private-company watch item rather than high-conviction ranked candidate.

66
Astroscale
lowweak
Opp 5
Risk 3

Thesis: No direct negative evidence is available. Remaining risk comes from the lack of post-recent evidence window evidence proving contract conversion, revenue realization, or mission execution scale.

Why now: Why now is relatively constructive because a named partnership for on-orbit services can matter over a long strategic horizon, but exact timing and materiality cannot be validated from the reviewed sources because only membership rationale is visible.

Caveats: Membership rationale references article ID: but the reviewed sources provide no or article summary. Relation counts are present in support metadata, but relations are context-only unless separately policy-gated. No direct positive or negative evidence arrays are populated.

67
Axelspace Corporation
lowweak
Opp 3
Risk 3

Thesis: No material negative evidence is present; risk is mainly execution and evidence-gap risk because current launch timing, deployment success, and monetization are not substantiated by the available reviewed sources evidence (: unavailable in reviewed sources).

Why now: Why now is weak because the reviewed sources references a potentially important constellation expansion but provides no post-recent evidence window available evidence to confirm status or timing.

Caveats: No current evidence is provided for No direct evidence remained after the recent evidence filter. Recency of constellation expansion cannot be validated from reviewed sources fields.

68
CAS Space
lowweak
Opp 2
Risk 3

Thesis: Risk is modestly elevated because the membership rationale describes IPO and reusable rocket development ambitions, both of which imply capital intensity and execution risk, but there is no available adverse evidence.

Why now: There is no usable dated evidence available after recent evidence filtering, so the reviewed sources does not provide a clear timing catalyst.

Caveats: The membership rationale references an IPO and Lijian-1 launch activity, but those source articles are not included with ranking-usable details in these reviewed sources.

69
CesiumAstro
lowweak
Opp 5
Risk 3

Thesis: The positive financing evidence is stale relative to the reviewed sources' 90-day recent evidence window. The article is dated February 14, 2026, which the reviewed sources say was dropped by the recent evidence filter, so there is no current-window evidence confirming whether financing momentum, backlog conversion, or product adoption continued

Why now: There is no fresh catalyst inside the 90-day evidence window. The visible article was published on February 14, 2026 and is outside the cutoff date of March 29, 2026, so it is useful as background but weak for recency-sensitive ranking

Evidence
  • February 14, 2026: 'CesiumAstro (US) raised a $270M Series C round (total funding: $655M). The company provides out-of-the-box communication systems for satellites, UAVs, launch vehicles, and other space or airborne platforms.' spaceambition.substack.com

Caveats: The visible positive article is outside the 90-day recent evidence window cutoff and was dropped from reviewed evidence. External supporting source context is allowed as evidence context but is not merged into primary data source.

70
ClearSpace
mediummedium
Opp 7
Risk 3

Thesis: Risks center on execution and evidence quality rather than explicit adverse news. The financing article carries internal chronology ambiguity because the page was published in 2026 but references a January 19, 2023 financing round, and the overall reviewed sources lack direct negative events, contract-performance data, or milestone completion proof.

Why now: Why now is supported by recent dated context: on June 24, 2026, SpaceNews reported ClearSpace signed an MOU with Shield Space to develop sovereign space defense capabilities for the UK and allies, indicating adjacent market expansion. On May 19, 2026, the company site said it had finalized a EUR 26.7 million Series A and was ramping operations ahead of ClearSpace-1 scheduled to launch in 2026. These dated items fit a 1 year+ horizon because they point to ongoing commercialization and mission preparation.

Evidence
  • Published June 24, 2026, SpaceNews said Shield Space and ClearSpace signed an MOU on June 23 to develop sovereign space defense capabilities for the UK and allies using ClearSpace's in-orbit servicing capabilities. spacenews.com
  • Published May 19, 2026, ClearSpace said it finalized a EUR 26.7 million Series A and was ramping operations ahead of ClearSpace-1, scheduled to launch in 2026. clearspace.today
  • Published May 19, 2026, the company timeline states ESA designated ClearSpace to lead the first mission to remove debris from orbit by 2028 and lists collaborations, certification, and prior mission selections. clearspace.today

Caveats: Most evidence is supporting article context, not direct positive events. The financing article published on May 19, 2026 references January 19, 2023 for the Series A round, so funding recency versus page recency should not be conflated.

71
D-Orbit
lowweak
Opp 4
Risk 3

Thesis: No direct negative evidence is present. Risk remains moderate because the evidence base is only one cited article with no available direct events, leaving uncertainty on commercialization, timeline, and conversion from demonstration activity to durable revenue.

Why now: Why now is the partnership/demo claim referenced in article ID, but the reviewed sources includes neither nor explicit article timing beyond the article ID prefix, limiting recency precision.

Caveats: Opportunity rests on membership rationale rather than fully available direct evidence. Referenced article ID has no in the reviewed sources. Demo activity is not the same as proven commercial traction.

72
Dawn Aerospace
mediummedium
Opp 7
Risk 3

Thesis: Risk is non-trivial because the thesis depends on execution of a global rollout in a capital-intensive reusable space transportation market, but the reviewed sources does not show direct adverse events. Risk is therefore moderate rather than high.

Why now: The key catalyst is recent and explicit: on June 16, 2026 the company announced the Series B close and said the proceeds will finance global rollout and scaling of commercial and operational teams in the US and Europe.

Evidence
  • June 16, 2026. Summary says Dawn Aerospace closed a $25 million Series B at a $195 million post-money valuation to accelerate global expansion of reusable space transportation. dawnaerospace.com
  • The company states the Series B will directly finance global rollout, scaling commercial and operational teams in the US and Europe to support its expanding international customer base. dawnaerospace.com

Caveats: Evidence comes from a company-published article, so it is not fully independent. No direct structured positive event row is provided beyond supporting article context.

73
Earth Eye Co
lowweak
Opp 2
Risk 3

Thesis: Because the reviewed sources frames the company around surveillance/spy satellite activity rather than commercial traction, and provides no direct positive operating evidence, the name screens as a limited-visibility watchlist with modest evidence-based risk.

Why now: Why now is weak because there are no available post-recent evidence window evidence, no article summaries, and no clear near- or long-horizon catalyst beyond generic association with a surveillance satellite.

Caveats: Membership rationale cites article IDs and, but the reviewed sources provide no. Company is private and evidence coverage inside the recent evidence window is empty.

74
EDGX
lowweak
Opp 4
Risk 3

Thesis: Execution and financing risk remain material because the reviewed sources contain no kept direct evidence on follow-on funding, customer adoption, revenue conversion, or post-demo performance; technology demonstration does not by itself prove scale-up.

Why now: The membership support references articles, and, implying a narrative of funding plus orbital demonstration, but active evidence remains empty after recent evidence filtering, limiting recency confidence.

Caveats: In-orbit demo claim appears only in reviewed sources rationale, not available direct evidence. No evidence confirms whether the prior seed round falls within the current decision horizon relevance. No direct adverse evidence is present, but that is not proof of low fundamental risk.

75
Ellipsis Drive
lowweak
Opp 4
Risk 3

Thesis: Risk is mostly commercialization uncertainty. The reviewed sources does not provide direct negative evidence, but it also lacks direct available proof of revenue, customer conversion, or broader market adoption.

Why now: Why now is the reviewed sources' claim that the company addresses a key EO data-processing bottleneck and has space-agency support, referenced to article ID: though no or timestamp detail was provided.

Caveats: Claims come from membership rationale rather than direct evidence. Referenced article ID: lacks a reviewed sources. Support from agencies and target users is weaker than demonstrated contracted revenue.

76
EON Space Labs
lowweak
Opp 1
Risk 3

Thesis: The reviewed sources' clearest adverse context is that EON Space Labs was identified as one of the Indian private space companies affected by a PSLV failure, which could create execution, schedule, or financing ripple effects over a 1 year+ horizon, though the underlying article detail is not surfaced in the scoring evidence fields.

Why now: Why now is stronger than for most names here because the phase2 rationale specifically ties EON Space Labs to a PSLV failure context via article: implying a concrete event rather than generic company context. However, conviction remains low because the reviewed sources omits the underlying event summary and dates in the evidence exposed here.

Caveats: The adverse signal appears only in phase2 rationale, not in direct negative evidence. No article summary, quote, or timing detail is provided in the scoring fields. Impact magnitude on EON specifically cannot be quantified from these reviewed sources alone.

77
Eycore
mediumweak
Opp 5
Risk 3

Thesis: Risk remains moderate because the reviewed sources offers only one supporting article context and no direct positive event row beyond that summary, leaving unclear whether the satellite is generating revenue, delivering performance, or leading to follow-on orders.

Why now: Why now is the dated first-satellite launch article from May 5, 2026, which is recent within the 90-day recent evidence window and relevant to a long-horizon de-risking story, though still early-stage.

Evidence
  • SpaceNews summary says Eycore launched Eycore-1, an Earth observation satellite equipped with the company's synthetic aperture radar technology. Article timestamp May 5, 2026. spacenews.com

Caveats: Evidence is supporting article context only, not a stronger structured positive event row. Single-article universe limits corroboration. No financing, customer, revenue, or performance follow-through evidence is provided.

78
GITAI
mediummedium
Opp 6
Risk 3

Thesis: Execution and commercialization risk remain meaningful because the retained evidence is still mainly company-provided article context and a technology demonstration milestone, not third-party validated contract wins, revenue conversion, or mission success; an undated directory listing that GITAI is 'operating' is weaker context and not recency proof.

Why now: The key catalyst is recent and inside recent evidence window: on June 16, 2026, GITAI announced completion of the S3 flight model for an on-orbit servicing demonstration mission, which is directly relevant to a 1 year+ horizon because it may precede launch, demonstration, and downstream defense/commercial adoption over the next year.

Evidence
  • GITAI announced completion of the flight model of its S3 robotic satellite mission, a technology demonstration mission designed to validate advanced on-orbit servicing technologies. gitai.tech
  • The mission is described as demonstrating the company's modular spacecraft architecture supporting future defense-focused low Earth orbit constellation services. gitai.tech

Caveats: Primary evidence is from the company itself. No retained independent customer, contract, or revenue evidence is provided. The spaceindex.io entry is undated and should not be treated as recency proof.

79
Goonhilly Earth Station Ltd
lowweak
Opp 3
Risk 3

Thesis: The same reviewed sources rationale says Goonhilly is being acquired by Intuitive Machines, which can create integration, ownership, and business-state uncertainty over a 1 year+ horizon. Because no retained dated evidence are available, this risk is only moderately ranked.

Why now: The only 'why now' available is the reviewed sources' statement that Goonhilly is being acquired by Intuitive Machines, cited in phase-2 support, and: but no, timestamps, or retained evidence are provided, so recency and sequence cannot be validated.

Caveats: The reviewed sources rationale states Goonhilly has ground-station/COMSAT revenue and is being acquired by Intuitive Machines, tied to, and: but no or retained evidence are present. Coverage debug still shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Because chronology cannot be verified, transaction-state claims should be treated cautiously.

80
ICEYE
highstrong
Opp 9
Risk 3

Thesis: The reviewed sources does not show material adverse company-specific events; main risk is that most support is financing/context evidence rather than audited operating metrics or margins.

Why now: On June 9, 2026 ICEYE disclosed a €450 million primary Series F at valuation above €10 billion, with total round size above €1 billion including secondary, and later June context also referenced a €300 million revolving credit facility and additional sovereign satellite demand; those are recent business-state signals for a 1 year+ horizon.

Evidence
  • Published June 9, 2026: ICEYE raised EUR 450 million in a primary Series F led by General Atlantic at a valuation of over EUR 10 billion; total funding round exceeded EUR 1 billion including secondary. iceye.com
  • Published June 9, 2026: Iceye raised more than 1 billion euros to expand SAR satellite systems. spacenews.com
  • Published June 15, 2026: article says ICEYE raised €450 million primary capital at >€10 billion valuation, total round above €1 billion, and had originated a €300 million three-year revolving credit facility on May 22, 2026. beinsure.com

Caveats: Some support is supporting article context rather than company-specific positive evidence. Several supporting demand/customer references are undated, so recency is uncertain for those claims.